Neflamapimod Phase 2a Data in Primary Progressive Aphasia Show Exposure-Linked NfL Decline

Author profile image Aggregator
0 comments
In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.

Source: NeurologyLive Published 19 Nov 2026 Imported 19 Nov 2026 Relevancy: Not reviewed

Read the article